Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that it presented preclinical data on Supinoxin™ (RX-5902) at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia. This presentation entitled, “Targeting localization and function of the RNA helicase DDX5/p68 with 1-(3,5-dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)” was co-authored by Frances Fuller-Pace Ph.D., Division of Cancer Research, University of Dundee, United Kingdom and Rexahn scientists.
In the present study, Supinoxin™ (RX-5902) was shown to dose-dependently decrease the migration of human triple negative breast cancer cells (MDA-MB-231) in a preclinical model of cancer cell metastasis.
Dr. Fuller-Pace commented, “RX-5902 was effective in blocking the migration of human triple negative breast cancer cells (MDA-MB231). This is very encouraging, suggesting its potential utility for the treatment of malignant tumors.”
“We continue to be encouraged by the preclinical and clinical data seen with Supinoxin™. Phosphorylated p68 appears to be involved in cancer cell survival and growth as well as tumor metastasis, suggesting that Supinoxin™ may play a role in treating difficult cancers such as triple negative breast cancer where metastatic disease is a common occurrence and is one of the main factors that impact prognosis,” commented Ely Benaim, M.D., Rexahn’s Chief Medical Officer.
Supinoxin is currently in a Phase I dose-escalation clinical trial in cancer patients with solid tumors with clinical data expected in the first half of 2015.(Original Source)
Shares of Rexahn closed yesterday at $0.7747 . RNN has a 1-year high of $1.08 and a 1-year low of $0.65. The stock’s 50-day moving average is $0.74 and its 200-day moving average is $0.74.
On the ratings front, MLV & Co. analyst Vernon Bernardino initiated coverage with a Buy rating on RNN and a price target of $1.25, In a report issued on March 20. The current price target implies an upside of 61.4% from current levels, In a report issued on March 20. The current price target implies an upside of 61.4% from current levels
According to TipRanks.com, Bernardino has a total average return of -7.3%, a 43.1% success rate, and is ranked #3449 out of 3575 analysts.
Rexahn Pharmaceuticals Inc is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs.